51job

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

A |     北交所上市公司彩客科技登龙虎榜：当日换手率达到22.54% 每经讯，2026年8月25日，北交所上市公司彩客科技（920206，收盘价：46.5元）登上龙虎榜，交易方式是连续竞价，披露原因是当日换手率达到22.54%，成交数量620.41万股，成交金额3.11亿元。    (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

B | 买一席位为东吴证券股份有限公司上海西藏南路证券营业部，买入701.99万元；卖一席位为国泰海通证券股份有限公司浙江宁波解放北路营业部，卖出1077.53万元。         （记者曾健辉）     免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。

C |     每日经济新闻     。

Current article:http://www.tibiantasangnenti.buzz/w8u/eqxbm.htm

Published on:01:22:29